FDA Perspectives: An Initial Report of CDER's Recall Root Cause Research Project (Part II) - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

FDA Perspectives: An Initial Report of CDER's Recall Root Cause Research Project (Part II)
The authors discuss how their research will help FDA in its identification of areas of emphasis in pre- and postapproval evaluation of products and processes.

Pharmaceutical Technology
Volume 35, Issue 1, pp. 66-69


Use of systematic RCA is effective at determining the origin of a defect or problem. DMPQ has made substantial progress in the initial investigation of selected recall areas using data mining, statistical analysis, and RCA. A few root cause determinations are presented in this paper to illustrate the use of RCA and the type of data amassed for each incident through data mining. Future papers in this series will discuss the root causes of specific defect focus areas such as Class I recalls, B. cepacia contamination, subpotency, and dissolution.

1 Please see FDA guidances for additional information on recalls (3).
2 that is, during management review of suitability of the process for launch, or during subsequent process performance monitoring

Richard Friedman is division director, Michael Smedley is branch chief, and Israel Santiago is a compliance officer in the Recalls, Shortages and Certificates Branch; all in the Division of Manufacturing and Product Quality, Office of Compliance, Center for Drug Evaluation and Research, US Food and Drug Administration. Lynn Torbeck* is the principal statistician at Torbeck and Assoc., 2000 Dempster, Evanston, IL 60202-1017, 847.424.1314,
. He is also a member of Pharmaceutical Technology's editorial advisory board.

*To whom all correspondence should be addressed.

Submitted: Sept. 30, 2010. Accepted Nov. 19, 2010.


1. L. Torbeck et al., Pharm.Technol. 33 (8), 42–45 (2009).

2. L. Torbeck, FDA/PDA Joint Regulatory Conference (Washington DC, Sept. 9, 2008).

3. FDA, Guidance for Industry: Product Recalls (Rockville, MD, Feb. 2009).

4. ICH, ICH Q10, Pharmaceutical Quality System, June 2008.

5. FDA, Guidance for Industry: FDA Quality Systems Approach to Pharmaceutical CGMP Regulations (Rockville, MD, Sept. 2006).

This article represents the views of the authors and not of FDA.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here